Business Context and Reporting Period
This Form 8-K was filed by Cardio Diagnostics Holdings, Inc. on December 6, 2023, reporting events occurring on December 5, 2023. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Chicago, IL. Its common stock (CDIO) and redeemable warrants (CDIOW) are listed on The Nasdaq Stock Market LLC.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material change reported is the resolution of a listing compliance issue. Previously, on September 21, 2023, the Company received notice from Nasdaq that its common stock closing bid price had been below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The Company was granted 180 days to regain compliance. On December 5, 2023, Nasdaq notified the Company that the closing bid price had been $1.00 or greater for the 10 consecutive business days from November 20, 2023, through December 4, 2023. Consequently, the Company has regained compliance, and Nasdaq has closed the matter.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies beyond the resolution of the specific listing deficiency. The primary risk addressed was the potential delisting due to low stock price, which has been mitigated by the recent price recovery.
Investor Verification Checklist
- Verify the current trading price of CDIO to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm that Nasdaq has officially closed the compliance matter regarding Rule 5550(a)(2).
- Review the press release dated December 6, 2023 (Exhibit 99.1) for any additional details on the stock price recovery.
- Monitor future filings for any recurrence of bid price deficiencies.